Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients

J Neural Transm Park Dis Dement Sect. 1992;4(2):173-8. doi: 10.1007/BF02251480.


20 patients with Parkinson's disease and a fluctuating response to chronic treatment with conventional L-dopa preparations participated in an open randomized trial comparing two sustained-release L-dopa preparations (Madopar HBS, Sinemet CR4). While a majority (15 patients, 7 on Madopar HBS and 8 on Sinemet CR4) showed a favourable response after 2 months of slow-release L-dopa treatment the clinical benefit remained stable in only 2 patients on Madopar HBS and 3 patients on Sinemet CR4 over the entire follow-up period of 12 months. Reasons for treatment failure were increased peak-dose or biphasic dyskinesias or prolonged "off"-periods. This preliminary study failed to demonstrate clinically significant advantages of one slow-release principle over the other.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Benserazide / administration & dosage*
  • Benserazide / therapeutic use
  • Carbidopa / administration & dosage*
  • Carbidopa / therapeutic use
  • Delayed-Action Preparations
  • Drug Combinations
  • Follow-Up Studies
  • Humans
  • Levodopa / administration & dosage*
  • Levodopa / therapeutic use
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology


  • Delayed-Action Preparations
  • Drug Combinations
  • benserazide, levodopa drug combination
  • carbidopa, levodopa drug combination
  • Levodopa
  • Benserazide
  • Carbidopa